Insider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 51,043 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) COO Douglas F. Kling sold 51,043 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at approximately $928,400. The trade was a 53.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

NewAmsterdam Pharma Trading Up 5.1%

NAMS traded up $1.06 during trading on Thursday, hitting $21.98. The stock had a trading volume of 599,934 shares, compared to its average volume of 741,886. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $27.29. The company has a 50 day simple moving average of $19.28 and a 200-day simple moving average of $20.25. The firm has a market cap of $2.47 billion, a PE ratio of -11.69 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. As a group, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on NAMS. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price objective for the company. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research note on Thursday. They set a "neutral" rating and a $27.00 target price on the stock. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $41.30.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors have recently modified their holdings of the stock. Quarry LP bought a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at about $25,000. GF Fund Management CO. LTD. acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at approximately $50,000. National Bank of Canada FI bought a new stake in NewAmsterdam Pharma in the 4th quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. boosted its position in NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after acquiring an additional 596 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of NewAmsterdam Pharma by 130.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after acquiring an additional 3,390 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.